Vision loss in giant cell arteritis patients treated with alternate-day corticosteroids: comment on the article by Hoffman et al.
Spiera
Robert F
RF
Kupersmith
Mark
M
Paget
Stephen
S
Spiera
Harry
H
D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D013700:Giant Cell Arteritis / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D015337:Multicenter Studies as Topic; D010919:Placebos; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D016896:Treatment Outcome; D015354:Vision, Low / Q000209:etiology*
D018501:Antirheumatic Agents; D010919:Placebos; D011241:Prednisone; D008727:Methotrexate